These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37591588)

  • 21. Adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan.
    Qamar FN; Yousafzai MT; Khaliq A; Karim S; Memon H; Junejo A; Baig I; Rahman N; Bhurgry S; Afroz H; Sami U
    Vaccine; 2020 Apr; 38(19):3518-3523. PubMed ID: 32201138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Vaccine Safety After the First Public Sector Introduction of Typhoid Conjugate Vaccine-Navi Mumbai, India, 2018.
    Longley AT; Date K; Luby SP; Bhatnagar P; Bentsi-Enchill AD; Goyal V; Shimpi R; Katkar A; Yewale V; Jayaprasad N; Horng L; Kunwar A; Harvey P; Haldar P; Dutta S; Gidudu JF
    Clin Infect Dis; 2021 Aug; 73(4):e927-e933. PubMed ID: 33502453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase II/III, Multicenter, Observer-blinded, Randomized, Non-inferiority and Safety, study of typhoid conjugate vaccine (EuTCV) compared to Typbar-TCV® in healthy 6 Months-45 years aged participants.
    Ok Baik Y; Lee Y; Lee C; Kyung Kim S; Park J; Sun M; Jung D; Young Jang J; Jun Yong T; Woo Park J; Jeong S; Lim S; Hyun Han S; Keun Choi S
    Vaccine; 2023 Mar; 41(10):1753-1759. PubMed ID: 36774331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E's Vi-capsular polysaccharide-CRM
    Thuluva S; Paradkar V; Matur R; Turaga K; Gv SR
    Hum Vaccin Immunother; 2022 Nov; 18(5):2043103. PubMed ID: 35333702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study.
    Bilcke J; Antillón M; Pieters Z; Kuylen E; Abboud L; Neuzil KM; Pollard AJ; Paltiel AD; Pitzer VE
    Lancet Infect Dis; 2019 Jul; 19(7):728-739. PubMed ID: 31130329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination.
    Vadrevu KM; Raju D; Rani S; Reddy S; Sarangi V; Ella R; Javvaji B; Mahantshetty NS; Battu S; Levine MM
    Vaccine; 2021 Oct; 39(45):6682-6690. PubMed ID: 34625288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infections Among Nepalese Children: A Protocol for a Phase III, Randomized Control Trial.
    Theiss-Nyland K; Shakya M; Colin-Jones R; Voysey M; Smith N; Karkey A; Dongol S; Pant D; Farooq YG; Neuzil KM; Shrestha S; Basnyat B; Pollard AJ
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S67-S73. PubMed ID: 30845329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso.
    Sirima SB; Ouedraogo A; Barry N; Siribie M; Tiono AB; Nébié I; Konaté AT; Berges GD; Diarra A; Ouedraogo M; Soulama I; Hema A; Datta S; Liang Y; Rotrosen ET; Tracy JK; Jamka LP; Neuzil KM; Laurens MB
    Int J Infect Dis; 2021 Jan; 102():517-523. PubMed ID: 33176205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Typhoid Conjugate Vaccine: An Urgent Tool to Combat Typhoid and Tackle Antimicrobial Resistance.
    Saha SK; Tabassum N; Saha S
    J Infect Dis; 2021 Dec; 224(12 Suppl 2):S788-S791. PubMed ID: 34528685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal.
    Shakya M; Colin-Jones R; Theiss-Nyland K; Voysey M; Pant D; Smith N; Liu X; Tonks S; Mazur O; Farooq YG; Clarke J; Hill J; Adhikari A; Dongol S; Karkey A; Bajracharya B; Kelly S; Gurung M; Baker S; Neuzil KM; Shrestha S; Basnyat B; Pollard AJ;
    N Engl J Med; 2019 Dec; 381(23):2209-2218. PubMed ID: 31800986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial.
    Nampota-Nkomba N; Nyirenda OM; Khonde L; Mapemba V; Mbewe M; Ndaferankhande JM; Msuku H; Masesa C; Misiri T; Mwakiseghile F; Patel PD; Patel P; Johnson-Mayo I; Pasetti MF; Heyderman RS; Tracy JK; Datta S; Liang Y; Neuzil KM; Gordon MA; Laurens MB;
    Lancet Glob Health; 2022 Sep; 10(9):e1326-e1335. PubMed ID: 35961356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multi-centre, post-marketing surveillance study of Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar TCV®) in India.
    Reddy R; Reddy B; Sarangi V; Reddy S; Ella R; Vadrevu KM
    Hum Vaccin Immunother; 2022 Dec; 18(1):1947761. PubMed ID: 34242128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of typhoid conjugate vaccine against culture-confirmed typhoid in a peri-urban setting in Karachi: A case-control study.
    Batool R; Tahir Yousafzai M; Qureshi S; Ali M; Sadaf T; Mehmood J; Ashorn P; Naz Qamar F
    Vaccine; 2021 Sep; 39(40):5858-5865. PubMed ID: 34465474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parental acceptance of typhoid conjugate vaccine for children aged 6 months to 15 years in an outbreak setting of Lyari Town Karachi, Pakistan.
    Batool R; Yousafzai MT; Qureshi S; Muhammad S; Qazi I; Sadaf T; Ashorn P; Qamar FN
    Vaccine; 2023 Aug; 41(37):5376-5382. PubMed ID: 37463829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How Can the Typhoid Fever Surveillance in Africa and the Severe Typhoid Fever in Africa Programs Contribute to the Introduction of Typhoid Conjugate Vaccines?
    Jeon HJ; Im J; Haselbeck A; Holm M; Rakotozandrindrainy R; Bassiahi AS; Panzner U; Mogeni OD; Seo HJ; Lunguya O; Jacobs J; Okeke IN; Terferi M; Owusu-Dabo E; Dougan G; Carey M; Steele AD; Kim JH; Clemens JD; Andrews JR; Park SE; Baker S; Marks F
    Clin Infect Dis; 2019 Oct; 69(Suppl 6):S417-S421. PubMed ID: 31665772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, immunogenicity and non-interference of concomitant Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV®) and measles or measles-mumps-rubella vaccines in 8-9 months-old Indian children.
    Vadrevu KM; Dugyala R; Mahantashetti NS; Khalatkar V; Murthy K; Mogre S; Mitra M
    Hum Vaccin Immunother; 2022 Dec; 18(7):2150030. PubMed ID: 36476258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Typhoid Fever Surveillance, Incidence Estimates, and Progress Toward Typhoid Conjugate Vaccine Introduction - Worldwide, 2018-2022.
    Hancuh M; Walldorf J; Minta AA; Tevi-Benissan C; Christian KA; Nedelec Y; Heitzinger K; Mikoleit M; Tiffany A; Bentsi-Enchill AD; Breakwell L
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(7):171-176. PubMed ID: 36795626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
    Jin C; Gibani MM; Moore M; Juel HB; Jones E; Meiring J; Harris V; Gardner J; Nebykova A; Kerridge SA; Hill J; Thomaides-Brears H; Blohmke CJ; Yu LM; Angus B; Pollard AJ
    Lancet; 2017 Dec; 390(10111):2472-2480. PubMed ID: 28965718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children.
    Patel PD; Patel P; Liang Y; Meiring JE; Misiri T; Mwakiseghile F; Tracy JK; Masesa C; Msuku H; Banda D; Mbewe M; Henrion M; Adetunji F; Simiyu K; Rotrosen E; Birkhold M; Nampota N; Nyirenda OM; Kotloff K; Gmeiner M; Dube Q; Kawalazira G; Laurens MB; Heyderman RS; Gordon MA; Neuzil KM;
    N Engl J Med; 2021 Sep; 385(12):1104-1115. PubMed ID: 34525285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An open-label, comparative, single dose, clinical Phase Ⅰ study to assess the safety and immunogenicity of typhoid conjugate vaccine (Vi-CRM197) in healthy Filipino adults.
    Choi SK; Baik YO; Kim CW; Kim SK; Oh IN; Yoon H; Yu D; Lee C
    Vaccine; 2021 May; 39(19):2620-2627. PubMed ID: 33849723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.